DBV Technologies SA – (NASDAQ:DBVT) saw a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 1,239,316 shares, a growth of 28.3% from the February 15th total of 966,186 shares. Based on an average daily volume of 520,947 shares, the short-interest ratio is currently 2.4 days.
DBVT has been the topic of several research analyst reports. JMP Securities initiated coverage on DBV Technologies in a report on Friday, November 17th. They set an “outperform” rating on the stock. BidaskClub cut DBV Technologies from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 6th. Zacks Investment Research cut DBV Technologies from a “hold” rating to a “sell” rating in a report on Monday, December 25th. Finally, Citigroup set a $57.00 price target on DBV Technologies and gave the company a “buy” rating in a report on Wednesday, February 14th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. DBV Technologies currently has a consensus rating of “Hold” and a consensus target price of $49.63.
DBV Technologies (NASDAQ DBVT) opened at $23.11 on Tuesday. DBV Technologies has a 1-year low of $20.08 and a 1-year high of $50.57.
TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/03/13/short-interest-in-dbv-technologies-sa-dbvt-increases-by-28-3.html.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.